The pro forma equity value of the portion of the combined company attributable to Tevogen Bio Inc (“Tevogen Bio”) stockholders is an expected $1.2 billion. Tevogen Bio is an advanced-stage specialty ...
New York, NY, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Semper Paratus Acquisition Corporation (Nasdaq: LGST) (“Semper Paratus”), a publicly traded special purpose acquisition company, today announced the ...
Get an in-depth profile of Semper Paratus Acquisition Corp Unit, including a general overview of the company's business and key management, as well as employee data and location and contact ...
WARREN, N.J.--(BUSINESS WIRE)--Tevogen Bio Inc ("Tevogen Bio") is looking forward to and continues to work toward the anticipated closing of its proposed business combination with Semper Paratus ...
Semper Paratus will hold an extraordinary general meeting of its stockholders (the "Special Meeting") at which shareholders will be asked to consider and vote upon proposals to approve the Business ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results